Abstract Number: 1723 • ACR Convergence 2022
CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…Abstract Number: 1890 • ACR Convergence 2022
The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study
Background/Purpose: Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage…Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…Abstract Number: 0025 • ACR Convergence 2022
Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells
Background/Purpose: The progressive degradation of osteoarthritis (OA) cartilage has been associated with articular innate immune responses (IIR) mediated by the Toll-like receptor 4 (TLR4). Additionally,…Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…Abstract Number: 0047 • ACR Convergence 2022
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…Abstract Number: 2260 • ACR Convergence 2022
Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting over 32.5 million US adults and characterized by pain, stiffness, swelling and functional disability.…Abstract Number: 0474 • ACR Convergence 2022
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…Abstract Number: 0589 • ACR Convergence 2022
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Background/Purpose: This study aimed to: 1- Evaluate the levels of NAD+ and gene transcripts involved in its metabolism in Rheumatoid Arthritis (RA) patients. 2- Analyse…Abstract Number: 0597 • ACR Convergence 2022
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist…Abstract Number: 0536 • ACR Convergence 2021
The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…Abstract Number: 0694 • ACR Convergence 2021
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…Abstract Number: 0733 • ACR Convergence 2021
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
ACR Meeting Abstracts